Trial Profile
A Retrospective, Single-Center Study Investigating Ipilimumab and Nivolumab Combination Followed by Nivolumab Maintenance Therapy in Patients with Metastatic Uveal Melanoma (MUM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 27 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.